SCHEMBL5115335

SCHEMBL5115335

Cc1csc2nc(-n3cccn3)nc(NCc3ccccc3)c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 6/20 0.48
PDE5A O76074 1/20 0.38
PTGS1 P23219 1/20 0.38
TBXAS1 P24557 1/20 0.38
PTGS2 P35354 1/20 0.38
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
CHRM4 P08173 1/20 0.37
LMNA P02545 3/20 0.37
HTT P42858 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
VCP P55072 2/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 2/20 0.37
MAPT P10636 2/20 0.37
ALOX12 P18054 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
RAB9A P51151 2/20 0.37
RXFP1 Q9HBX9 1/20 0.37
NOD2 Q9HC29 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5123189 0.92 ESR1 (0.49) ESR1CHRM4HTTMAPTRXFP1
SCHEMBL5125399 0.86 ESR1 (0.48) ESR1ALDH1A1GAAMAPT
SCHEMBL5129891 0.84 ESR1 (0.42) ESR1LMNASMN1; SMN2GAARAB9A
SCHEMBL5128850 0.84 MEN1 (0.44) ESR1PDE5APDE3BPDE3AALDH1A1
SCHEMBL5129121 0.84 ESR1 (0.47) ESR1PDE5APTGS1TBXAS1PTGS2
SCHEMBL5128242 0.83 ALDH1A1 (0.42) ESR1PDE5ACHRM4LMNAHTT
SCHEMBL5129101 0.83 ALDH1A1 (0.46) ESR1PDE5ALMNAHTTSMN1; SMN2
SCHEMBL5118379 0.83 ALDH1A1 (0.48) PDE5APTGS1TBXAS1PTGS2PDE3B
SCHEMBL5122820 0.83 PDE5A (0.58) ESR1PDE5APTGS1TBXAS1PTGS2
SCHEMBL5122305 0.82 ESR1 (0.45) ESR1PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
CN-1875023-A Use of thienopyrimidines MERCK PATENT GMBH (DE) 2006-12-06 CN disclosed
EP-1685136-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 2006-08-02 EP disclosed
WO-2005047292-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 2005-05-26 WO disclosed
US-6432950-B1 ANTICANCER AGENTS; KILLING CANCER CELLS CELL PATHWAYS 2002-08-13 US disclosed
US-6133271-A Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives CELL PATHWAYS, INC. (US) 2000-10-17 US disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 ESR1 2256/4885PDE5A 2002/4885PTGS1 1420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.